Sonthalia Sidharth, Agrawal Mahima, Talwar Ankur, Goldust Mohamad
Department of Dermatology and Dermatosurgery, Skinnocence: The Skin Clinic and Research Centre, Gurugram, Haryana, India.
Department of Dermatology and STD, LHMC and Associated Hospitals, New Delhi, India.
Indian Dermatol Online J. 2019 Aug 28;10(5):567-570. doi: 10.4103/idoj.IDOJ_453_18. eCollection 2019 Sep-Oct.
Recent anecdotal evidence suggests that oral low-dose naltrexone (LDN) is effective for Hailey-Hailey disease (HHD) but suffers the limitation of immediate relapse following cessation of the medication. With lack of safety data on long-term administration of LDN, we explored the utility of a topical diphenhydramine/ketamine (DK) cream in maintaining the remission achieved with LDN. A 42-year-old male with treatment-refractory HHD remitted with 5 mg naltrexone/day but relapsed on stopping the drug. Symptoms abated after restarting LDN. The impact of regular twice-a-day application of a specially formulated DK cream containing diphenhydramine (2% w/w) and ketamine (1% w/w) over the affected areas on maintenance of remission was explored till the next relapse. Our approach enabled dose reduction of naltrexone to 3 mg/day without loss of treatment benefit. After 3-month overlap of naltrexone and DK cream, withdrawal of naltrexone maintained remission with only the topical regime with no adverse effects till 4 months of follow-up. The use of topical agents with anti-inflammatory, antipruritic, antinociceptive, and naltrexone-mimicking properties merits exploration as an option to provide short but significant period of naltrexone-free maintenance of remission to patients with HHD.
近期的轶事证据表明,口服低剂量纳曲酮(LDN)对黑利-黑利病(HHD)有效,但存在停药后立即复发的局限性。由于缺乏LDN长期给药的安全性数据,我们探讨了外用苯海拉明/氯胺酮(DK)乳膏在维持LDN诱导的缓解方面的效用。一名42岁难治性HHD男性患者,服用5mg/天纳曲酮后病情缓解,但停药后复发。重新开始使用LDN后症状减轻。我们探讨了每天两次在受累区域涂抹一种特别配制的含苯海拉明(2%w/w)和氯胺酮(1%w/w)的DK乳膏对维持缓解的影响,直至下次复发。我们的方法能够将纳曲酮剂量减至3mg/天,且不影响治疗效果。在纳曲酮和DK乳膏重叠使用3个月后,停用纳曲酮仅采用局部用药方案仍维持缓解,直至随访4个月均无不良反应。使用具有抗炎、止痒、镇痛和模拟纳曲酮特性的局部用药作为一种选择,为HHD患者提供短期但显著的无纳曲酮缓解维持期,值得探索。